Temozolomide, Bevacizumab, Lithium and Radiation Treatment for Newly Diagnosed High Grade Glioma: A Phase II Study
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2015
At a glance
- Drugs Bevacizumab (Primary) ; Lithium (Primary) ; Temozolomide (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 05 Nov 2015 Time Frame for primary endpoint changed from 6 months to 50 months as per NCT.
- 12 Jan 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
- 26 Feb 2014 Planned End Date changed from 1 Apr 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.